Business
Acquisition of further interest in Renalytix AI
Acquisition of further interest in Renalytix AI.
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3144X EKF Diagnostics Holdings PLC 26 April 2019 \n\nEKF Diagnostics Holdings plc\n(\"EKF\" or the \"Company\")\n \nAcquisition of further interest in Renalytix AI plc\n \nEKF Diagnostics Holdings (AIM: EKF), the AIM quoted point-of-care business, notes the announcement by Renalytix AI plc (AIM: RENX) (\"RenalytixAI\"), that on 26 April 2019 EKF Diagnostics plc (\"EKF\") acquired 100,074 ordinary RenalytixAI shares of £0.0025 each. \n \nChristopher Mills, Julian Baines and Richard Evans (Chairman, CEO and FD/COO respectively of EKF) are each directors of, and directly and indirectly shareholders in, RenalytixAI.\n \nFollowing the above transaction, which took place at an average price of 123.5973 pence per RenalytixAI share, EKF's interest in RenalytixAI is now in 2,677,981 Ordinary Shares, representing 4.98% of RenalytixAI's issued share capital.\n \nFurther details of the underlying trades are disclosed in the announcement by RenalytixAI in this regard.\n \nEnquiries:\n \n\n\n\nEKF Diagnostics Holdings plc \n\n\nwww.ekfdiagnostics.com\n\n\n\n\nChristopher Mills, Non-Executive Chairman\n\n\nTel: 029 2071 0570\n\n\n\n\nJulian Baines, CEO \n\n\n\n\n\n\n\nRichard Evans, FD & COO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nN+1 Singer (Nomad & Broker)\n\n\nTel: 020 7496 3000\n\n\n\n\nAubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)\nTom Salvesen (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited Tel: 020 7933 8780 or [email protected] \n\n\n\n\nPaul McManus/ Lianne Cawthorne\n\n\nMob: 07980 541 893 / 07584 391 303\n\n\n\n \n \nAbout EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)\nEKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across...